RECOMBINANT PROTEINS / EPO
Erythropoietin (EPO) is a glycoprotein hormone best known for its role in stimulating bone marrow to produce red blood cells. Consequently, recombinant human EPO is an important biopharmaceutical drug for treatment of anemia. Four forms, namely epoetin alfa, epoetin beta, epoetin delta and darbepoetin alfa, are distinguished mainly by their glycosylation.
Recombinant EPO is produced using mammalian cell lines, such as CHO, which are engineered to express the protein. After cell culture and harvest, downstream purification is required to achieve the necessary product purity. A popular approach uses an ion exchange column followed by a reversed-phase C4 column step.
In addition to EPO, other recombinant proteins that are purified with silica gel include colony stimulating factors such as filgrastim and sargramostim.
EPO Purification Phase
Our P Series C4 silica gel is bonded with butyl groups to provide the moderate hydrophobicity that is best suited for the purification of erythropoietin and similar recombinant proteins. It is available in 300Å pore size to accommodate these large molecules.
Go to P SeriesBulk Silica Gel for Recombinant Protein Purification
The following DAISOGEL products are suitable for the purification of recombinant proteins such as EPO. Click a silica gel pore size to learn more.
| Recommended Pore Size (Å) | |||||
|---|---|---|---|---|---|
| C8 Phase | C4 Phase | APS Phase | Phenyl Phase | ODS Phase | |
| P Series | — | 300 | — | — | — |
Did you know?
Even though the first epoetin alfa was approved back in 1989, the market is still increasing due to a rise in the number of patients suffering from anemic conditions induced from cancer, HIV, and other afflictions.